Related Experiment Videos
[Effect of molsidomine on hemodynamics in patients with dilated cardiomyopathy]
Insights
Molsidomine effectively reduced blood pressure and vascular resistance in patients with chronic heart failure. While it improved cardiac output slightly, side effects like hypotension limited its use in one case.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic heart failure (CHF) management
- Non-ischaemic dilatative cardiomyopathy
Purpose:
- Evaluate Molsidomine's hemodynamic effects in CHF patients
- Assess impact on arterial and pulmonary pressures, cardiac index, and vascular resistance
Summary:
- Molsidomine (4 mg IV followed by 3 mg/hr infusion) significantly decreased systemic blood pressure, pulmonary artery pressure, and pulmonary wedge pressure.
- Total peripheral and pulmonary vascular resistance were markedly reduced.
- Cardiac index showed a slight, non-significant increase, and heart rate remained stable. One patient discontinued treatment due to hypotension and nausea.
Impact:
- Provides insights into Molsidomine's vasodilatory effects in heart failure.
- Highlights potential benefits in reducing hemodynamic load.
- Underscores the need for careful monitoring due to potential side effects.
Abstract:
The effect of 4 mg Molsidomine iv. followed by a continuous infusion of 3 mg per hour for 3 hours on arterial blood pressure, pulmonary artery pressure, cardiac index, peripheral and pulmonary vascular resistance and heart rate was evaluated in eleven patients suffering from chronic heart failure caused by non-ischaemic dilatative cardiomyopathy (NYHA II-III). A significant decrease in systemic blood pressure, systolic and mean pulmonary artery pressure and pulmonary wedge pressure was observed and also a marked decrease in total peripheral and pulmonary vascular resistance. There was a slight, but not significant increase in cardiac index. The heart rate did not change significantly. Treatment had to be stopped in one patient because of side effects (hypotension, nausea).